1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Pfizer Pulls Plug But iTeos Has High Hopes For IDO1 Inhibitor

 
• By Kevin Grogan

The Belgian biotech has regained the rights to an early-stage IDO1 inhibitor that has failed a Phase I trial but iTeos believes the drug's penetration to the brain makes EOS200271 a significant asset.

Doors
Door closes, another opens: iTeos upbeat despite Pfizer pact ending • Source: Shutterstock

News that Pfizer Inc. is returning the rights to its indoleamine 2,3-dioxygenase (IDO1) inhibitor is a surprise but represents an opportunity for iTeos Therapeutics SA, according to the Belgian biotech's CEO Michel Detheux.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer